Novo Nordisk A/S (NYSE:NVO) gapped up prior to trading on Monday . The stock had previously closed at $46.48, but opened at $46.88. Novo Nordisk A/S shares last traded at $47.48, with a volume of 2,235,685 shares changing hands.

NVO has been the subject of a number of research reports. Bank of America Corp. cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, August 8th. Goldman Sachs Group Inc. lowered Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, June 28th. Citigroup Inc. restated a “buy” rating on shares of Novo Nordisk A/S in a report on Wednesday, August 3rd. Finally, Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Monday, July 11th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $61.00.

The firm has a market cap of $120.45 billion and a price-to-earnings ratio of 22.41. The company has a 50 day moving average price of $52.62 and a 200 day moving average price of $53.74.

The firm also recently declared a dividend, which will be paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th will be given a dividend of $0.326 per share. The ex-dividend date of this dividend is Thursday, August 11th.

An institutional investor recently raised its position in Novo Nordisk A/S stock. Rhumbline Advisers raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 5.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,800 shares of the company’s stock after buying an additional 1,100 shares during the period. Rhumbline Advisers’ holdings in Novo Nordisk A/S were worth $1,208,000 as of its most recent filing with the SEC.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.